ResearcherMedical College of WisconsinNo recent work listed
Chad A. Barnes
Matched on OpenAlex author ID A5052302539. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: none · 2022: 1 paper
Papers 7
- Novel Considerations in Surgical Management of Individuals with Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.hoc.2022.07.004↗
- Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
- Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
- Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00460↗
- Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
- Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
- Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Susan Tsai · 7 shared papers, 2017–2022 · strength 0.86
- Paper Novel Considerations in Surgical Management of Individuals with Pancreatic Adenocarcinoma. DOI 10.1016/j.hoc.2022.07.004↗
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Bradley A. Erickson · 6 shared papers, 2017–2020 · strength 0.53
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- William Adrian Hall · 6 shared papers, 2017–2020 · strength 0.53
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Ben George · 6 shared papers, 2017–2020 · strength 0.53
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Mohammed Aldakkak · 6 shared papers, 2017–2020 · strength 0.53
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Douglas B. Evans · 6 shared papers, 2017–2020 · strength 0.53
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Kathleen K. Christians · 6 shared papers, 2017–2020 · strength 0.53
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Callisia Nathelee Clarke · 5 shared papers, 2017–2020 · strength 0.43
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Paper Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. DOI 10.3389/fonc.2020.00460↗
- Kulwinder S. Dua · 3 shared papers, 2019–2020 · strength 0.28
- Paper Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable an… DOI 10.1016/j.surg.2020.04.031↗
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Naveen M. Kulkarni · 2 shared papers, 2020 · strength 0.19
- D. Wittmann · 2 shared papers, 2020 · strength 0.19
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. DOI 10.3389/fonc.2020.00460↗
- Parag P. Tolat · 2 shared papers, 2019–2020 · strength 0.18
- Paper Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer … DOI 10.3389/fonc.2020.00500↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Catherine E. Hagen · 2 shared papers, 2019–2020 · strength 0.18
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. DOI 10.1016/j.surg.2019.05.010↗
- Ashley N. Krepline · 2 shared papers, 2017–2020 · strength 0.16
- Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
- Paper Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? DOI 10.1007/s11605-017-3544-5↗
- Mandana Kamgar · 1 shared paper, 2020 · strength 0.10
- Neil R. Jariwalla · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.